Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRTX Fresh Tracks Therapeutics	$0.94 -0.5%	$0.94	$0.03 ▼ $1.03	$5.59M	0.54	2,709 shs	2,402 shs
OVID Ovid Therapeutics	$0.34 +9.1%	$0.30	$0.24 ▼ $1.47	$22.36M	0.08	413,075 shs	1.80 million shs
PASG Passage Bio	$0.33 +1.2%	$0.37	$0.26 ▼ $1.33	$20.26M	1.71	369,651 shs	426,778 shs
VYNE VYNE Therapeutics	$1.62 +18.2%	$1.20	$0.85 ▼ $4.30	$20.84M	1.56	180,026 shs	4.96 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRTX Fresh Tracks Therapeutics	0.00%	0.00%	0.00%	0.00%	+5.06%
OVID Ovid Therapeutics	+9.06%	+15.92%	+17.71%	-2.00%	-51.87%
PASG Passage Bio	+1.23%	-15.49%	-7.85%	-13.39%	-63.82%
VYNE VYNE Therapeutics	+18.25%	+72.27%	+62.00%	-4.71%	+1.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	4.6028 of 5 stars	3.6	3.0	0.0	4.6	4.0	2.5	0.6
PASG Passage Bio	2.786 of 5 stars	3.5	2.0	0.0	0.0	2.5	1.7	1.3
VYNE VYNE Therapeutics	2.7593 of 5 stars	3.5	3.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRTX Fresh Tracks Therapeutics	0.00	N/A	N/A	N/A
OVID Ovid Therapeutics	3.20	Buy	$3.13	811.08% Upside
PASG Passage Bio	3.00	Buy	$7.50	2,172.73% Upside
VYNE VYNE Therapeutics	3.00	Buy	$6.25	285.80% Upside

Current Analyst Ratings Breakdown

Latest FRTX, VYNE, OVID, and PASG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
4/25/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.75 ➝ $4.50
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRTX Fresh Tracks Therapeutics	$10.06M	0.56	N/A	N/A	$1.66 per share	0.56
OVID Ovid Therapeutics	$570K	42.79	N/A	N/A	$0.96 per share	0.36
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A
VYNE VYNE Therapeutics	$500K	49.28	N/A	N/A	$3.53 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRTX Fresh Tracks Therapeutics	-$5.69M	-$1.41	N/A	∞	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
VYNE VYNE Therapeutics	-$39.83M	-$0.99	N/A	N/A	N/A	-6,974.55%	-71.89%	-58.94%	8/13/2025 (Estimated)

Latest FRTX, VYNE, OVID, and PASG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/8/2025	Q1 2025	VYNE VYNE Therapeutics	-$0.29	-$0.20	+$0.09	-$0.20	$0.05 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRTX Fresh Tracks Therapeutics	N/A	N/A	N/A
OVID Ovid Therapeutics	0.22	4.93	4.93
PASG Passage Bio	N/A	3.74	3.74
VYNE VYNE Therapeutics	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FRTX Fresh Tracks Therapeutics	25.04%
OVID Ovid Therapeutics	72.24%
PASG Passage Bio	53.48%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
FRTX Fresh Tracks Therapeutics	0.23%
OVID Ovid Therapeutics	13.10%
PASG Passage Bio	5.00%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FRTX Fresh Tracks Therapeutics	20	5.97 million	5.96 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
PASG Passage Bio	130	62.15 million	59.04 million	Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.48 million	Not Optionable

FRTX, VYNE, OVID, and PASG Headlines

Recent News About These Companies

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 46.8% in May

June 18, 2025 | americanbankingnews.com

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges

May 31, 2025 | investing.com

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations

May 12, 2025 | finance.yahoo.com

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.

April 27, 2025 | nasdaq.com

VYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque Psoriasis

April 27, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)

April 26, 2025 | markets.businessinsider.com

VYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | finanznachrichten.de

VYNE shares tumble after FDA clinical hold on psoriasis drug study

April 25, 2025 | za.investing.com

Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis

April 25, 2025 | biospace.comB

FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns

April 25, 2025 | fiercebiotech.comF

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

April 25, 2025 | benzinga.com

VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | globenewswire.com

Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

April 9, 2025 | finanznachrichten.de

Artiva Biotherapeutics Names New Chief Medical Officer

April 8, 2025 | marketwatch.com

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2025 | markets.businessinsider.com

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2025 | globenewswire.com

H.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)

March 11, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

March 7, 2025 | markets.businessinsider.com

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

March 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
By Jeffrey Neal Johnson | June 18, 2025
View Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
Government Mandate Sends eVTOL Stocks Flying
By Jeffrey Neal Johnson | June 10, 2025
View Government Mandate Sends eVTOL Stocks Flying
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
By Thomas Hughes | June 11, 2025
View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge

FRTX, VYNE, OVID, and PASG Company Descriptions

Fresh Tracks Therapeutics NASDAQ:FRTX

$0.94 -0.01 (-0.53%)

As of 02/28/2025

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Ovid Therapeutics NASDAQ:OVID

$0.34 +0.03 (+9.06%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.33 -0.01 (-2.62%)

As of 04:32 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Passage Bio NASDAQ:PASG

$0.33 +0.00 (+1.23%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.35 +0.02 (+6.06%)

As of 06/26/2025 07:49 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

VYNE Therapeutics NASDAQ:VYNE

$1.62 +0.25 (+18.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.66 +0.04 (+2.47%)

As of 04:44 AM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time